Valor202020212022202320242025TTMGastos comerciales, generales y administrativos16.47 M22.94 M18.05 M14.51 M9.64 M7 M6.44 MInvestigación y desarrollo7.96 M3.89 M1.51 M1.39 M53 K9 000—Beneficio operativo-12.78 M-35.53 M-18.82 M-13.94 M-3.65 M-2.5 M-3.81 MTotal de ingresos no operativos18.37 M10.11 M2.31 M48 K31 K4.61 M-733 KGastos por intereses, netos de intereses capitalizados47 K20 K—————Ingresos no operativos, una vez deducidos los gastos por intereses17.58 M-20 K2.28 M002.3 M-1.54 MIngresos/gastos extraordinarios740 K10.11 M33 K48 K31 K2.31 M805 KBeneficio antes de impuestos-6.15 M-16.13 M-15.6 M-13.16 M-4.31 M-2.33 M-5.04 MParticipación en los beneficios———————Impuestos-124 K2 00014 K8 0008 0008 000—Participación minoritaria-1.37 M-1.47 M-236 K-5 0000——Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-4.66 M-14.66 M-15.38 M-13.16 M-7.04 M-2.34 M-9.32 MOperaciones suspendidas———-821 K———Beneficio neto-4.66 M-14.66 M-15.38 M-13.98 M-7.04 M-2.34 M-9.32 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-4.66 M-14.66 M-15.38 M-13.98 M-7.04 M-2.34 M-9.32 MBeneficio básico por acción——-25.65-11.3-5.17-1.71-5.72Beneficio por acción diluido——-25.65-11.3-5.17-1.71-5.72Número medio de acciones ordinarias——599.39 K1.24 M1.36 M1.37 M—Acciones diluidas——599.39 K1.24 M1.36 M1.37 M—EBITDA-16.47 M-34.48 M-18.05 M-12.96 M-2.81 M-2.25 M-3.76 MEBIT-17.09 M-35.53 M-18.53 M-13.24 M-2.87 M-2.28 M-3.79 MCosto de los ingresos4.31 M8.71 M9.8 M3.3 M2.96 M3.1 M3.12 MOtros costes de producción4.31 M—2.47 M444 K154 K0—Amortización y depreciación (flujo de caja)618 K1.04 M479 K287 K58 K32 K27 K
Arcadia Biosciences, Inc. - Common Stock
Arcadia Biosciences is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.
It has developed a reduced-gluten and enhanced starch variety of wheat under the name GoodWheat. Arcadia also has a joint venture with Bioceres called Verdeca, which has developed and is commercializing HB4 technology in soybeans that gained FDA approval in 2017. HB4 soybeans have increased yield up to 30% while being more resistant to abiotic stress such as drought.